Cory Booker raised about $2 million in first quarter

Newark Mayor Cory Booker's (D) Senate campaign raised about $2 million in the first quarter of 2013, the campaign announced Monday.

The campaign said it raised $1.9 million from 2,300 contributors in the first three months of 2013. Sixty-five percent of the contributions were of $200 or less, the campaign said.

Booker's campaign said it ended the quarter with $1.6 million cash on hand.

"The support we’re seeing from people across New Jersey and around the country reflects the work Mayor Booker has done to make Newark a better place to live," Booker finance director Lauren Dikis said in a statement.

Booker is running for retiring Sen. Frank Lautenberg's (D-N.J.) Senate seat.

In March Booker's campaign brought on Kevin Griffis, who previously worked on President Obama's 2008 presidential campaign, as a senior communications advisor.

View Comments

View the original article here

UPDATE 1-Lilly loses ground in fourth quarter to generics

Jan 29 (Reuters) - Eli Lilly and Co said on Tuesday that fourth-quarter earnings fell as competition from generic drugs, particularly for its top-selling schizophrenia drug Zyprexa, drove revenue lower.

The U.S. drugmaker earned $827 million, or 74 cents per share, compared with $858 million, or 77 cents per share, a year earlier.

Excluding special items such as asset impairments and restructuring, Lilly earned 85 cents per share. Analysts, on average, were expecting 78 cents per share.

Revenue dropped by about 1 percent to $5.96 billion, above Wall Street expectations of $5.81 billion.

The company said falling sales from the loss of the Zyprexa patent was partly offset by gains in sales of other drugs and its animal health products.

Lilly said it expects earnings this year to increase to $3.82 to $3.97 per share, excluding special items. It said profit would benefit by 7 cents per share from a research and development tax credit that was delayed until this year due to the late signing of federal legislation.

It predicted sales will be flat to a bit higher this year, despite expected generic competition in December for its $5-billion-a-year antidepressant Cymbalta.

View the original article here